oral tirzepatide clinical trials Pill: FDA Status 2026, How It Works & Availability Lilly orforglipron oral GLP-1 phase

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effectsincluding anti-inflammatory, ...

While GLP-1 medications have shown remarkable results for weight loss, they may also lead to some muscle loss

Methods In 10,310 participants from the Atherosclerosis Risk in Communities (ARIC) Study (aged 4670 years, ~55% women, ~20% Black adults) without diabetes at baseline (19901992), we used Cox regression to characterise age- and sex-adjusted associations of prediabetes with ~30 year incidence of complications (composite and separately), including atherosclerotic CVD (ASCVD), heart failure, chronic kidney disease (CKD) and all-cause mortality before and after accounting for intervening incidence of diabetes, modelled as a time-varying variable

In a 2021 study published in the New England Journal of Medicine, participants taking Semaglutide lost an average of 14.9% of their body weight over 68 weeks